首发精神分裂症患者血液中神经元特异性烯醇化酶和髓鞘碱性蛋白的改变

目的 通过测定首发精神分裂症患者髓鞘碱性蛋白(MBP)和神经元特异性烯醇化酶(NSE),探讨是否有神经系统损伤。方法 选择88例首发精神分裂症患者(患者组)和30例对照(对照组)测定血液中MBP和NSE,采用双抗体夹心酶标免疫分析法检测。并在入组第1天及第8周后分别评定阳性和阴性症状量表(PANSS)量表。结果 患者组MBP(7.9±4.5)μg/L]和NSE(19.4±6.9)μg/L]含量明显高于对照组(4.3±0.4)μg/L,(8.0±2.8)μg/L],t:12.70,P<0.01;t=7.20,P<0.01。患者组MBP和NSE与PANSS总分减分率呈负相关(r=-0.236,P=0.025:r=-0.298,P=0.005)。结论 精神分裂症患者可能存在神经系统损伤,且受损程度可能与疗效有关。

Serum neuro-specific enolase and myelin basic protein in patients with schizophrenia

Objective To study whether patients with schizophrenia have cerebral injury. Methods The serumneuro-specific enolase (NSE) and myelin basic protein (MBP) in 88 schizophrenic patients and 30 controls were determined with double antibody sandwich immunoassay method. The patients were assessed with the Positive and Negative Syndromes Scale ( PANSS) pre-treatment and at the 8th weekend of treatment. Results There were significant difference of serum NSE and MBP concentrations between the patients and controls (t = 12. 70, P < 0. 01; t =1.20, P < 0. 01 ) . And the NSE and MBP levels had significantly negative correlation with the reduction of PANSS total scores in patients ( r = - 0. 236, P = 0. 025; r = -0. 298, P =0.005). Conclusion It is suggested that there is cerebral injury in patients with schizophrenia.